3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Fluorouracil
128
Leucovorin
120
Oxaliplatin
101
Irinotecan
89
Bevacizumab
55
Cetuximab
44
Capecitabine
40
Folfox protocol
29
Panitumumab
22
Colonoscopy
17
Chemotherapy, Adjuvant
16
Floxuridine
15
Early Intervention, Educational
15
Erlotinib Hydrochloride
13
Surveys and Questionnaires
11
IFL protocol
11
Counseling
11
Celecoxib
11
Immunohistochemistry
10
Gemcitabine
10
Psychiatric Rehabilitation
9
Methods
8
Magnetic Resonance Spectroscopy
8
Gene Expression Profiling
8
Exercise
8
Dexamethasone
8
sargramostim
7
Sorafenib
7
Radiotherapy
7
Nivolumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Colonic Neoplasms
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA